Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial

William W Busse, Paul M O'Byrne, Eugene R Bleecker, Jan Lötvall, Ashley Woodcock, Leslie Andersen, Wesley Hicks, Jodie Crawford, Loretta Jacques, Ludovic Apoux, Eric D Bateman, William W Busse, Paul M O'Byrne, Eugene R Bleecker, Jan Lötvall, Ashley Woodcock, Leslie Andersen, Wesley Hicks, Jodie Crawford, Loretta Jacques, Ludovic Apoux, Eric D Bateman

Abstract

Background: The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β2 agonist vilanterol (VI) is in development for asthma and chronic obstructive pulmonary disease.

Objective: To assess the safety and tolerability of FF/VI over 52 weeks in patients with asthma.

Methods: Patients (aged ≥12 years; on inhaled corticosteroid) were randomised (2:2:1) to FF/VI 100/25 µg or FF/VI 200/25 µg once daily in the evening, or fluticasone propionate (FP) 500 µg twice daily. Safety evaluations included adverse events (AEs), non-fasting glucose, potassium, 24-h urinary cortisol excretion, ophthalmic assessments, heart rate and pulse rate.

Results: On-treatment AEs were similar across groups (FF/VI 66-69%; 73% FP). Oral candidiasis/oropharyngeal candidiasis was more common with FF/VI (6-7%) than FP (3%). Twelve serious AEs were reported; one (worsening hepatitis B on FP) was considered drug related. Statistically significant cortisol suppression was seen with FP compared with both FF/VI groups at Weeks 12 and 28 (ratios [95% CI] to FP ranged from 1.43 [1.11 to 1.84] to 1.67 [1.34 to 2.08]; p≤0.006), but not at Week 52 (ratios to FP were 1.05 [0.83 to 1.33] for FF/VI 100/25 µg and 1.09 [0.87 to 1.38] for FF/VI 200/25 µg). No clinically important changes in non-fasting glucose, potassium, QT interval corrected using Fridericia's formula (QTc[F]) or ophthalmic assessments were reported. Pulse rate (10 min post dose [Tmax], Week 52) was significantly increased with FF/VI versus FP (3.4 bpm, 95% CI 1.3 to 5.6; p=0.002 [FF/VI 100/25 µg]; 3.4 bpm, 95% CI 1.2 to 5.6; p=0.003 [FF/VI 200/25 µg]). Mean heart rate (24-h Holter monitoring) decreased from screening values in all groups (0.2-1.1 bpm FF/VI vs 5 bpm FP; Week 52).

Conclusions: FF/VI (100/25 µg or 200/25 µg) administered once daily over 52 weeks was well tolerated by patients aged ≥12 years with asthma. The overall safety profile of FF/VI did not reveal any findings of significant clinical concern. CLINICALTRIALS.GOV: NCT01018186.

Keywords: Asthma.

Figures

Figure 1
Figure 1
CONSORT/patient flow diagram.
Figure 2
Figure 2
Patient withdrawal from the study over time (intent-to-treat population).
Figure 3
Figure 3
24-h urinary cortisol (UC) excretion ratio to baseline at (A) Week 12, (B) Week 28 and (C) Week 52 (UC population).

References

    1. Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention. Updated 2011. (accessed 16 Jul 2012).
    1. National Institutes of Health Guidelines for the Diagnosis and Management of Asthma (EPR-3) 2007. NHLBI, August; 2007. NIH publication no. 08-4051. (accessed 16 Jul 2012).
    1. Colice GL. Emerging therapeutic options for asthma. Am J Manag Care 2011;(Suppl 3):S82–9
    1. Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010;10:1.
    1. Bateman ED, Bleecker ER, Busse W, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Resp Med 2012;106:642–50
    1. Bleecker ER, Bateman ED, Busse W, et al. Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy. Eur Respir J 2010;36(Suppl 54):204s
    1. Busse W, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in asthma patients symptomatic on medium doses of inhaled corticosteroid therapy: a randomised, placebo-controlled trial. Thorax 2012;67:35–41
    1. Lötvall J, Bateman ED, Bleecker ER, et al. 24-hour duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J 2012;40:570–9
    1. Sterling R, Lim J, Frith L, et al. Dose-related efficacy and optimal once-daily (OD) dosing interval of the long-acting beta2 agonist (LABA), vilanterol trifenatate (VI), in adults with persistent asthma. Respir Med 2012;106:1110–15
    1. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59–99
    1. Chylack LT, Wolfe JK, Singer DM, et al. The lens opacities classification system III. Arch Ophthalmol 1993;111:831–6
    1. Flovent™ prescribing information 2010. (accessed 16 Jul 2012).
    1. Adams NP, Bestall JC, Jones P, et al. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;4:CD003534.
    1. Kurt E, Yildirim H, Kiraz N, et al. Oropharyngeal candidiasis with dry-powdered fluticasone propionate: 500 microg/day versus 200 microg/day. Allergol Immunopathol (Madr) 2008;36:17–20
    1. Derom E, Louis R, Tiesler C, et al. Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. Eur Respir J 2009;33:1277–86
    1. Kempsford R, Allen A, Kelly K, et al. A repeat dose, double-blind, placebo-controlled ‘Thorough QT/QTc study’ to assess the cardiac safety of fluticasone furoate (FF) and vilanterol (VI) administered in combination. Am J Respir Crit Care Med 2012;185:A2841
    1. Bjerregaard P. Premature beats in healthy subjects 40–79 years of age. Eur Heart J 1982;3:493–503
    1. Stinson JC, Pears JS, Williams AJ, et al. Use of 24 h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers. Br J Clin Pharmac 1995;39:651–6
    1. Grimm W, Liedtke J, Muller H-H. Prevalence of potential noninvasive arrhythmia risk predictors in healthy, middle-aged persons. Ann Noninvasive Electrocardiol 2003;8:37–46

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit